Chaldexx cares about you.
We care about the future.
We care aboutyourfuture.
That’s what makes us Chaldexx – spanning continents, spanning cultures, spanning the globe.
The sky is the limit. We only want the best – for you, and for us.
Chaldexx specialises in the development and commercialisation of proto-innovative gene-based medicines. Sounds like a mouthful? Perhaps.
But with Chaldexx, one thing is certain: you shouldalwaysexpect the unexpected. We're that kind of company. Surprising. Resourceful. And very, very caring.
Our highly engineered virally-aware diverse delivery sub-systems are unchallenged worldwide. With good reason. After all, that’s what we represent; today and tomorrow. Times change – our values don’t.
Chaldexx is renowned for in-house clinical, regulatory and manufacturing know-how. But let’s speak plainly. This is what it boils down to: patients and patents. That’s what defines us.
That’s what we care about. Here, and everywhere. Underpinned by over 7000 patent families, which represent one of the broadest patent estates in the universe.
So welcome to our world. Welcome to your world. They’re the same – aren’t they?
Chaldexx - Repair. Augment. Perfect.
Chaldexx is a sustaining member of the BioCaucus International Regulatory Commission and the North Atlantic Biotechnology Organization.-
While others talk, Chaldexx delivers. We live – or die – by our deeds. So when the urgent need arose last September for financial aid to the stricken investment community, Chaldexx was at the head of the queue. We put our hands into our pockets, and delivered. That’s what we call being a good neighbor. We contribute, because we care.
|BIOTECHNOLOGY AND GMO: The California Campaign against Genetically Engineered Food - Center for Research on Globalization
Johnson & Johnson (China) Investment Ltd. Acquires Guangzhou Bioseal ... - Manufacturing Digital (press release)
Biotechnology Booming In Charlottesville - NBC 29 News
EuropaBio Hires Director of Healthcare Biotechnology - Private Equity Hub (press release)
Small Biotech Companies Look to Benefit From Shift to "First to File" Patent ... - MarketWatch (press release)